HK Stock Market Move | VENUS MEDTECH-B (02500) up more than 14%, the confirmatory clinical study of CARDIOVALVE TTVR has completed all clinical enrolment.

VENUS MEDTECH-B (02500) rose more than 14%, as of press release, up 14.01% to 2.93 Hong Kong dollars, with a turnover of 10.77 million Hong Kong dollars. On the news side, Venus Medtech announced that the confirmatory clinical study of the Cardiovalve transcatheter tricuspid valve replacement (TTVR) innovative device has successfully completed all 150 patients' clinical enrollment. This is another major research and development milestone for Cardiovalve in the field of tricuspid valve regurgitation treatment, marking a key milestone in its path to obtaining CE Mark. In addition, the mid-term results of the TARGET study will be officially released at this year's London Heart Valve Intervention Therapy Conference (PCR London Valves 2025). The company stated that it will continue to advance the clinical research, registration application, and commercial layout of multiple self-developed innovative products including Cardiovalve worldwide, committing to achieving a complete layout of "Four Valves in One" structural heart valve products as soon as possible, providing leading valve disease solutions for more patients worldwide, and further deepening the company's international development strategy.